OncoPharm cover image

Lirafugratinib + LITESPARK011

OncoPharm

00:00

Overall Survival Remains Immature

John Bazar discusses immature overall-survival data, subsequent therapies, and uncertainty about whether the combination will ultimately improve survival over cabozantinib.

Play episode from 13:40
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app